{"id":39114,"date":"2025-08-12T16:42:03","date_gmt":"2025-08-12T08:42:03","guid":{"rendered":"https:\/\/flcube.com\/?p=39114"},"modified":"2025-08-12T16:42:04","modified_gmt":"2025-08-12T08:42:04","slug":"chinas-nhsa-publishes-preliminary-list-for-2025-national-reimbursement-drug-list-and-commercial-insurance-innovative-drug-list","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39114","title":{"rendered":"China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List"},"content":{"rendered":"\n

China’s National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025 National Reimbursement Drug List and the new Commercial Insurance Innovative Drug List on August 12, 2025. The public comment period for the lists will be open until August 18.<\/p>\n\n\n\n

Review Process and Results<\/strong>
From July 11 to July 20, 2025, the NHSA received a total of 718 applications for the basic medical insurance drug list, covering 633 drugs by molecular names. After the initial review, 534 products passed the formal review. This included 472 applications for drugs not yet on the list, covering 393 drugs. Of these, 310 drugs passed the preliminary review, marking a significant increase from the 249 that passed in 2024.<\/p>\n\n\n\n

Commercial Insurance Innovative Drug List<\/strong>
This year, the NHSA introduced a new Commercial Insurance Innovative Drug List, which received 141 applications covering 141 drugs. After the preliminary review, 121 drugs passed the formal review. A total of 79 drugs successfully passed the preliminary review for both the basic medical insurance list and the commercial insurance innovative drug list.<\/p>\n\n\n\n

Key Drugs Included<\/strong>
Several key immunotherapies have been included in the preliminary review list. Notably, Opdivo (nivolumab), a first-in-class PD-1 inhibitor, entered the list for new indications and rare disease conditions. Other PD-1\/L1 inhibitors that passed the preliminary review include penpulimab from Akeso, socazolimab from Zhaoke, and Tagitanlimab from Kelun Pharma.<\/p>\n\n\n\n

CAR-T Cell Therapies<\/strong>
Three CAR-T cell therapies also passed the preliminary review: Inaticabtagene Autoleucel from Juventas Cell Therapy, Equecabtagene Autoleucel from IASO Bio, and Zevorcabtagene Autoleucel from CARsgen Therapeutics.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025…<\/p>\n","protected":false},"author":1,"featured_media":39115,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[67,75,74],"class_list":["post-39114","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-nhsa-prev-smia","tag-price-negotiations","tag-rdl"],"yoast_head":"\nChina's NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025 National Reimbursement Drug List and the new Commercial Insurance Innovative Drug List on August 12, 2025. The public comment period for the lists will be open until August 18.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39114\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China's NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List\" \/>\n<meta property=\"og:description\" content=\"China's National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025 National Reimbursement Drug List and the new Commercial Insurance Innovative Drug List on August 12, 2025. The public comment period for the lists will be open until August 18.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39114\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-12T08:42:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-12T08:42:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1214.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List\",\"datePublished\":\"2025-08-12T08:42:03+00:00\",\"dateModified\":\"2025-08-12T08:42:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114\"},\"wordCount\":261,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1214.webp\",\"keywords\":[\"NHSA (prev. SMIA)\",\"Price negotiations\",\"RDL\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39114#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39114\",\"name\":\"China's NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1214.webp\",\"datePublished\":\"2025-08-12T08:42:03+00:00\",\"dateModified\":\"2025-08-12T08:42:04+00:00\",\"description\":\"China's National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025 National Reimbursement Drug List and the new Commercial Insurance Innovative Drug List on August 12, 2025. The public comment period for the lists will be open until August 18.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39114\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1214.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/1214.webp\",\"width\":1080,\"height\":608,\"caption\":\"China's NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39114#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List - Insight, China's Pharmaceutical Industry","description":"China's National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025 National Reimbursement Drug List and the new Commercial Insurance Innovative Drug List on August 12, 2025. The public comment period for the lists will be open until August 18.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39114","og_locale":"en_US","og_type":"article","og_title":"China's NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List","og_description":"China's National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025 National Reimbursement Drug List and the new Commercial Insurance Innovative Drug List on August 12, 2025. The public comment period for the lists will be open until August 18.","og_url":"https:\/\/flcube.com\/?p=39114","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-12T08:42:03+00:00","article_modified_time":"2025-08-12T08:42:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1214.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39114#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39114"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List","datePublished":"2025-08-12T08:42:03+00:00","dateModified":"2025-08-12T08:42:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39114"},"wordCount":261,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39114#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1214.webp","keywords":["NHSA (prev. SMIA)","Price negotiations","RDL"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39114#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39114","url":"https:\/\/flcube.com\/?p=39114","name":"China's NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39114#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39114#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1214.webp","datePublished":"2025-08-12T08:42:03+00:00","dateModified":"2025-08-12T08:42:04+00:00","description":"China's National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025 National Reimbursement Drug List and the new Commercial Insurance Innovative Drug List on August 12, 2025. The public comment period for the lists will be open until August 18.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39114#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39114"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39114#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1214.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1214.webp","width":1080,"height":608,"caption":"China's NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39114#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/1214.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39114","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39114"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39114\/revisions"}],"predecessor-version":[{"id":39116,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39114\/revisions\/39116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39115"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39114"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39114"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39114"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}